Citations

Showing 10 of 108081 citations.

Pragmatic evaluation of events and benefits of lipid lowering in older adults ( PREVENTABLE ): Trial design and rationale
Joseph, Jacob , Pajewski, Nicholas M. , Dolor, Rowena J , Sellers, Mary Ann, Perdue, Letitia , Peeples, Sheronda R., Henrie, Adam M., Woolard, Nancy , Benziger, Catherine P. , Mixon, Amanda S. , VanWormer, Jeffrey J. , Chatterjee, Ranee , Newby, L. Kristin , Cicek, Mine , Williams, Neely , Decker, Jake E., Ou, Jiafu , Choudhary, Gaurav , Gazmuri, Raúl J. , Schmader, Kenneth E. , Vaughan, Camille P. , Ambrosius, Walter T. , Williamson, Jeff D. , Johnson, Kimberly S. , Espinoza, Sara , Markland, Alayne D. , Bazzano, Lydia , Benziger, Catherine P , Shapiro, Michael D , Kistler, Christine E , Gill, Thomas M , Newby, L Kristin , Cicek, Mine S , Ou, Jiafu , Gazmuri, Raúl J , Vaughan, Camille P , Supiano, Mark A , Shah, Raj C , Alexander, Karen P , Pajewski, Nicholas M , Espinoza, Sara , Jones, W. Schuyler , Orkaby, Ariela R. , Shapiro, Michael D. , Polonsky, Tamar S. , Chamberlain, Alanna M. , Forman, Daniel E. , Knowlton, Kirk U. , Gill, Thomas M. , Hammill, Bradley G. , Rubinstein, Jack , Roumie, Christianne L. , Effron, Mark B , Cooper‐DeHoff, Rhonda M. , Supiano, Mark A. , Shah, Raj C. , Whittle, Jeff , Hernandez, Adrian F. , Alexander, Karen P.

Mayo Clinic

Journal of the American Geriatrics Society | April 21, 2023 | Volume: 71 | Issue: 6 | Pages: 1701-1713

10.1111/jgs.18312 | PMID 37082807 Get It

Abstract Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double‐blind, placebo‐controlled randomized pragmatic clinical trial, will compare high‐intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community‐dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin. Potential participants are identified using computable phenotypes derived from the electronic health record and local referrals from the community. Participants will undergo baseline cognitive testing, with physical testing and a blinded lipid panel if feasible. Cognitive testing and disability screening will be conducted annually. Multiple data sources will be queried for cardiovascular events, dementia, and disability; survival is site‐reported and supplemented by a National Death Index search. The primary outcome is survival free of new dementia or persisting disability. Co‐secondary outcomes are a composite of cardiovascular death, hospitalization for unstable angina or myocardial infarction, heart failure, stroke, or coronary revascularization; and a composite of mild cognitive impairment or dementia. Ancillary studies will offer mechanistic insights into the effects of statins on key outcomes. Biorepository samples are obtained and stored for future study. These results will inform the benefit of statins for increasing survival free of dementia and disability among older adults. This is a pioneering pragmatic study testing important questions with low participant burden to align with the needs of the growing population of older adults.
Revolutionizing Chronic Kidney Disease Management with Machine Learning and Artificial Intelligence
Krisanapan, Pajaree , Tangpanithandee, Supawit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Tangpanithandee, Supawit , Krisanapan, Pajaree , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | April 21, 2023 | Volume: 12 | Issue: 8 | Pages: 3018

10.3390/jcm12083018 | PMID 37109354 Get It

Chronic kidney disease (CKD) poses a significant public health challenge, affecting approximately 11% to 13% of the global population [...]
Vitamin D in Diabetes: Uncovering the Sunshine Hormone’s Role in Glucose Metabolism and Beyond
Wu, Jie , Atkins, Annette R. , Downes, Michael , Wei, Zong

Mayo Clinic

Nutrients | April 21, 2023 | Volume: 15 | Issue: 8 | Pages: 1997

10.3390/nu15081997 | PMID 37111216 Get It

Over the last decades, epidemiology and functional studies have started to reveal a pivotal role of vitamin D in both type 1 and type 2 diabetes pathogenesis. Acting through the vitamin D receptor (VDR), vitamin D regulates insulin secretion in pancreatic islets and insulin sensitivity in multiple peripheral metabolic organs. In vitro studies and both T1D and T2D animal models showed that vitamin D can improve glucose homeostasis by enhancing insulin secretion, reducing inflammation, reducing autoimmunity, preserving beta cell mass, and sensitizing insulin action. Conversely, vitamin D deficiency has been shown relevant in increasing T1D and T2D incidence. While clinical trials testing the hypothesis that vitamin D improves glycemia in T2D have shown conflicting results, subgroup and meta-analyses support the idea that raising serum vitamin D levels may reduce the progression from prediabetes to T2D. In this review, we summarize current knowledge on the molecular mechanisms of vitamin D in insulin secretion, insulin sensitivity, and immunity, as well as the observational and interventional human studies investigating the use of vitamin D as a treatment for diabetes.
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma
Cole, Kristina A. , Ijaz, Heba, Surrey, Lea F. , Santi, Mariarita , Liu, Xiaowei , Voss, Stephan D. , Fox, Elizabeth , Weigel, Brenda J. , Minard, Charles G. , Maris, John M. , Reid, Joel M.

Mayo Clinic

Cancer | April 20, 2023 | Volume: 129 | Issue: 14 | Pages: 2245-2255

10.1002/cncr.34786 | PMID 37081608 Get It

AbstractBackgroundInhibition of the WEE1 kinase by adavosertib (AZD1775) potentiates replicative stress from genomic instability or chemotherapy. This study reports the pediatric solid tumor phase 2 results of the ADVL1312 trial combining irinotecan and adavosertib.MethodsPediatric patients with recurrent neuroblastoma (part B), medulloblastoma/central nervous system embryonal tumors (part C), or rhabdomyosarcoma (part D) were treated with irinotecan and adavosertib orally for 5 days every 21 days. The combination was considered effective if there were at least three of 20 responses in parts B and D or six of 19 responses in part C. Tumor tissue was analyzed for alternative lengthening of telomeres and ATRX. Patient's prior tumor genomic analyses were provided.ResultsThe 20 patients with neuroblastoma (part B) had a median of three prior regimens and 95% had a history of prior irinotecan. There were three objective responses (9, 11, and 18 cycles) meeting the protocol defined efficacy end point. Two of the three patients with objective responses had tumors with alternative lengthening of telomeres. One patient with pineoblastoma had a partial response (11 cycles), but parts C and D did not meet the protocol defined efficacy end point. The combination was well tolerated and there were no dose limiting toxicities at cycle 1 or beyond in any parts of ADVL1312 at the recommended phase 2 dose.ConclusionThis is first phase 2 clinical trial of adavosertib in pediatrics and the first with irinotecan. The combination may be of sufficient activity to consider further study of adavosertib in neuroblastoma.
Knotless Arthroscopic Dorsal Scapholunate Capsulodesis: A Simplified Technique
Kakar, Sanjeev , Kalapos, Robert , Kakar, Sanjeev

Mayo Clinic

Journal of Wrist Surgery | April 20, 2023 | Volume: 13 | Issue: 05 | Pages: 463-468

10.1055/s-0043-1768134 | PMID 39296662 Get It

Abstract Background Partial dorsal tears of the scapholunate ligament are a common soft-tissue injury in the wrist. These injuries have been a challenging problem and have gone through evolutionary changes over time from different open to arthroscopic techniques. Objectives This study describes a knotless arthroscopic dorsal scapholunate (SL) capsulodesis technique using both the radiocarpal and midcarpal joint portals, indicated for acute or chronic reducible scapholunate instability. Methods Using arthroscopy, we pierce the dorsal capsule on both sides of the dorsal torn remains of the SL ligament with two 18-gauge needles, one loaded with a 2–0 suture and the other with a nitinol wire loop. The 2–0 suture is weaved through the nitinol loop to create a knotless mattress stitch within the midcarpal joint and reduce the torn SL ligament. Results In this article, we present the outcomes of a patient treated with this arthroscopic inside knotless technique in treating scapholunate instability. Conclusions This knotless arthroscopic scapholunate capsulodesis technique provides a simple method to performing an arthroscopic dorsal capsulodesis.
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
Li, Jiahui , Kalutkiewicz, Kyle, Mounajjed, Taofic, Therneau, Terry M. , Venkatesh, Sudhakar K. , Glaser, Kevin J. , Hoodeshenas, Safa , Shah, Vijay H. , Zhu, Zheng, Kalutkiewicz, Kyle J, Venkatesh, Sudhakar K , Sui, Yi , Manduca, A , Ehman, Richard , Allen, Alina M , Li, Jiahui , Lü, Xin , Zhu, Zheng Hong , Sui, Yi, Manduca, Armando , Ehman, Richard L. , Allen, Alina M. , Yin, Meng

Mayo Clinic

Hepatology | April 20, 2023 | Volume: 78 | Issue: 4 | Pages: 1200-1208

10.1097/hep.0000000000000417 | PMID 37080558 Get It

Background and Aims: The presence of at-risk NASH is associated with an increased risk of cirrhosis and complications. Therefore, noninvasive identification of at-risk NASH with an accurate biomarker is a critical need for pharmacologic therapy. We aim to explore the performance of several magnetic resonance (MR)-based imaging parameters in diagnosing at-risk NASH. Approach and Results: This prospective clinical trial (NCT02565446) includes 104 paired MR examinations and liver biopsies performed in patients with suspected or diagnosed NAFLD. Magnetic resonance elastography-assessed liver stiffness (LS), 6-point Dixon-derived proton density fat fraction (PDFF), and single-point saturation-recovery acquisition-calculated T1 relaxation time were explored. Among all predictors, LS showed the significantly highest accuracy in diagnosing at-risk NASH [AUCLS: 0.89 (0.82, 0.95), AUCPDFF: 0.70 (0.58, 0.81), AUCT1: 0.72 (0.61, 0.82), z-score test z >1.96 for LS vs any of others]. The optimal cutoff value of LS to identify at-risk NASH patients was 3.3 kPa (sensitivity: 79%, specificity: 82%, negative predictive value: 91%), whereas the optimal cutoff value of T1 was 850 ms (sensitivity: 75%, specificity: 63%, and negative predictive value: 87%). PDFF had the highest performance in diagnosing NASH with any fibrosis stage [AUCPDFF: 0.82 (0.72, 0.91), AUCLS: 0.73 (0.63, 0.84), AUCT1: 0.72 (0.61, 0.83), |z| <1.96 for all]. Conclusion: Magnetic resonance elastography-assessed LS alone outperformed PDFF, and T1 in identifying patients with at-risk NASH for therapeutic trials.
Outcomes and Patient Experience in Individuals With Longstanding Dizziness
Shah, Manami , Eggers, Scott D.Z. , Lohse, Christine M. , McCaslin, Devin L. , Staab, Jeffrey, Anderson, Ann, Eggers, Scott D, Lohse, Christine, Staab, Jeffrey P. , Anderson, Ann

Mayo Clinic

American Journal of Audiology | April 20, 2023 | Volume: 32 | Issue: 3S | Pages: 721-729

10.1044/2023_aja-22-00152 | PMID 37079889 Get It

Purpose: This study aimed to describe the relationship between changes in pre and post self-perceived dizziness handicap, scores on the patient health questionnaire, and perceptions of patient's value of being evaluated and managed by a multidisciplinary team. Method: Seventy-eight patients completed the Dizziness Handicap Inventory (DHI) and Patient Health Questionnaire–Fourth Edition (PHQ-4) questionnaires post multidisciplinary clinical consultations and testing for the chief complaints of dizziness, unsteadiness, vertigo, or balance problems. The diagnoses of each patient were recorded from the clinical reports of each specialty consultation and were classified as structural, functional, or psychiatric. They were contacted by phone at least 6 months after their visit to obtain feedback regarding their symptoms and overall patient experience. Results: The change in DHI total score did not differ significantly by diagnosis ( p = .56), indicating that patients experienced an improvement in DHI total score regardless of diagnosis. PHQ-4 anxiety scores worsened by a mean of 0.7 points for those with structural diagnoses ( p = .04), improved by a mean of 0.7 points for psychiatric diagnoses ( p = .16), and improved by a mean of 0.3 points for functional diagnoses ( p = .39). Only seven patients would not recommend the team to a family or friend; these patients tended to report worsening DHI total scores ( p = .27) compared to the significant improvement in DHI total scores for patients who would make such a recommendation ( p < .001). Similarly, only 13 patients did not feel the information they received had a positive impact; these patients tended to report worsening DHI total scores ( p = .18) compared to the significant improvement in DHI total scores for patients who did feel the information had a positive impact ( p < .001). Discussion: The assessment and management of patients with chronic dizziness is challenging due to symptoms arising from multiple etiologies. Our finding of a vast difference between high satisfaction and relatively unchanged dizziness handicap suggests that there is value in seeing a multidisciplinary team where consultations are unhurried, care is coordinated, and expectations regarding treatment can be managed.
Vesicourethral Anastomotic Stenosis Following Radical Prostatectomy: Risk Factors, Natural History, and Treatment Outcomes
Britton, Cameron J. , Sharma, Vidit , Fadel, Anthony , Bearrick, Elizabeth , Frank, Igor, Tollefson, Matthew K. , Karnes, R. Jeffrey , Fadel, Anthony E, Viers, Boyd R. , Fadel, Anthony , Findlay, Bridget L.

Mayo Clinic

Journal of Urology | April 20, 2023 | Volume: 210 | Issue: 2 | Pages: 312-322

10.1097/ju.0000000000003488 | PMID 37079876 Get It

CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization
Luebker, Sarah, Frech, Tracy , Skaug, Brian , Gordon, Jessica , Lakin, Kimberly S. , Bernstein, Elana J. , Luo, Yiming , Steen, Virginia , Moore, Duncan F. , Khanna, Dinesh , Castelino, Flavia V. , Chung, Lorinda, Kapoor, Puneet, Hant, Faye N. , Shanmugam, Victoria K. , VanBuren, John M. , Alvey, Jessica S. , Harding, Monica, Shah, Ankoor R. , Lebiedz‐Odrobina, Dorota, Thomas, Julie K. , Volkmann, Elizabeth R. , Molitor, Jerry A., Sandorfi, Nora , Chung, Leland W.K. , Luo, Yiming , Frech, Tracy M , Skaug, Brian , Bernstein, Elana J , Richardson, Carrie , Khanna, Dinesh , Volkmann, Elizabeth R , Chung, Lorinda , Luo, Yiming , Assassi, Shervin , Luo, Yiming, Shah, Ami A. , Hummers, Laura K , Chung, Lorinda, Shah, Ankoor, Makol, Ashima , Thomas, Julie K

Mayo Clinic

Rheumatology | April 20, 2023 | Volume: 62 | Issue: 10 | Pages: 3433-3438

10.1093/rheumatology/kead176 | PMID 37079727 Get It

Abstract Objectives SSc is associated with increased health-care resource utilization and economic burden. The Collaborative National Quality and Efficacy Registry (CONQUER) is a US-based collaborative that collects longitudinal follow-up data on SSc patients with &lt;5 years of disease duration enrolled at scleroderma centres in the USA. The objective of this study was to investigate the relationship between gastrointestinal tract symptoms and self-reported resource utilization in CONQUER participants. Methods CONQUER participants who had completed a baseline and 12-month Gastrointestinal Tract Questionnaire (GIT 2.0) and a Resource Utilization Questionnaire (RUQ) were included in this analysis. Patients were categorized by total GIT 2.0 severity: none-to-mild (0–0.49); moderate (0.50–1.00), and severe-to-very severe (1.01–3.00). Clinical features and medication exposures were examined in each of these categories. The 12-month RUQ responses were summarized by GIT 2.0 score categories at 12 months. Results Among the 211 CONQUER participants who met the inclusion criteria, most (64%) had mild GIT symptoms, 26% had moderate symptoms, and 10% severe GIT symptoms at 12 months. The categorization of GIT total severity score by RUQ showed that more upper endoscopy procedures and inpatient hospitalization occurred in the CONQUER participants with severe GIT symptoms. These patients with severe GIT symptoms also reported the use of more adaptive equipment. Conclusion This report from the CONQUER cohort suggests that severe GIT symptoms result in more resource utilization. It is especially important to understand resource utilization in early disease cohorts when disease activity, rather than damage, primarily contributes to health-related costs of SSc.
Economic Burden of Fatigue in Inflammatory Bowel Disease
Ananthakrishnan, Ashwin N. , Desai, Raj , Lee, Wan‐Ju , Griffith, Jenny, Chen, Naijun, Loftus, Edward V. , Ananthakrishnan, A N , Loftus, Edward V

Mayo Clinic

Crohn's & Colitis 360 | April 20, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad020 | PMID 37663925 Get It

AbstractBackgroundThis retrospective study gathered medical/pharmacy claims data on patients with inflammatory bowel disease (IBD) between January 01, 2000 and March 31, 2019 from the IBM MarketScan commercial claims database to assess the real-world impact of fatigue on healthcare costs in patients newly diagnosed with IBD.MethodsEligible participants were ≥18 years, newly diagnosed with IBD (≥2 separate claims), and had ≥12 months of continuous database enrollment before and after fatigue diagnosis. The date of fatigue diagnosis was the index date; participants were followed for 12 months post-index. Patients with (cases) or without (controls) fatigue were matched 1:1 by propensity score matching. Patients with evidence of prior IBD diagnosis/treatment, or those with a chronic disease other than IBD wherein fatigue is the primary symptom, were excluded. Healthcare resource utilization (HCRU), including hospitalizations, inpatient and outpatient visits, and associated costs were compared between cases and controls.ResultsMatched IBD cohorts (21 321 cases/21 321 controls) were identified (42% Crohn’s disease [CD] and 58% ulcerative colitis [UC]) with similar baseline characteristics (average age: 46 years; 60% female). Cases versus controls had significantly more all-cause outpatient visits (incidence rate ratio [IRR], 95% confidence intervals [95% CI]: 1.64 [1.61, 1.67], P &lt; .001) and all-cause hospitalizations (IRR [95% CI]: 1.92 [1.81, 2.04], P &lt; .001); as well as significantly higher all-cause total direct healthcare costs (mean: $24 620 vs. $15 324; P &lt; .001). Similar findings were observed for IBD-related outcomes, as well as in CD- and UC-specific subgroups.ConclusionsPresence of fatigue is associated with an increase in HCRU and total medical costs among patients newly diagnosed with IBD.